{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T14:40:12Z","timestamp":1781534412911,"version":"3.54.5"},"reference-count":38,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2018,6,6]],"date-time":"2018-06-06T00:00:00Z","timestamp":1528243200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2018,6,6]],"date-time":"2018-06-06T00:00:00Z","timestamp":1528243200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Dermatol"],"DOI":"10.1111\/bjd.16485","type":"journal-article","created":{"date-parts":[[2018,2,25]],"date-time":"2018-02-25T08:10:36Z","timestamp":1519546236000},"source":"Crossref","is-referenced-by-count":21,"title":["Effectiveness of systemic treatments for pyoderma gangrenosum: a systematic review of observational studies and clinical trials"],"prefix":"10.1093","author":[{"given":"A.C.R.","family":"Partridge","sequence":"first","affiliation":[{"name":"MD Program; Faculty of Medicine; University of Toronto; Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.W.","family":"Bai","sequence":"additional","affiliation":[{"name":"MD Program; Faculty of Medicine; University of Toronto; Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.F.","family":"Rosen","sequence":"additional","affiliation":[{"name":"Division of Dermatology; University of Toronto; Toronto Canada"},{"name":"Department of Medicine; University Health Network; Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.R.","family":"Walsh","sequence":"additional","affiliation":[{"name":"Division of Dermatology; University of Toronto; Toronto Canada"},{"name":"Department of Medicine; Sunnybrook Health Sciences Centre; Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.P.","family":"Gulliver","sequence":"additional","affiliation":[{"name":"Department of Medicine; Faculty of Medicine; Memorial University of Newfoundland; St. John's Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5695-6798","authenticated-orcid":false,"given":"P.","family":"Fleming","sequence":"additional","affiliation":[{"name":"Division of Dermatology; University of Toronto; Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,6,6]]},"reference":[{"key":"10.1111\/bjd.16485-BIB0001|bjd16485-cit-0001","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/j.1365-2133.2011.10565.x","article-title":"Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients","volume":"165","author":"Binus","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.16485-BIB0002|bjd16485-cit-0002","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/bmj.333.7560.181","article-title":"Diagnosis and treatment of pyoderma gangrenosum","volume":"333","author":"Brooklyn","year":"2006","journal-title":"BMJ"},{"key":"10.1111\/bjd.16485-BIB0003|bjd16485-cit-0003","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0190-9622(96)90428-4","article-title":"Pyoderma gangrenosum: classification and management","volume":"34","author":"Powell","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.16485-BIB0004|bjd16485-cit-0004","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1089\/wound.2011.0339","article-title":"Effective strategies for the\u00a0management of pyoderma gangrenosum","volume":"1","author":"Goodarzi","year":"2012","journal-title":"Adv Wound Care"},{"key":"10.1111\/bjd.16485-BIB0005|bjd16485-cit-0005","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/j.1468-3083.2009.03199.x","article-title":"Pyoderma gangrenosum: an updated review","volume":"23","author":"Ruocco","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.16485-BIB0006|bjd16485-cit-0006","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1365-4632.2004.02128.x","article-title":"Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria","volume":"43","author":"Su","year":"2004","journal-title":"Int J Dermatol"},{"key":"10.1111\/bjd.16485-BIB0007|bjd16485-cit-0007","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00105-009-1909-8","article-title":"Management of pyoderma gangrenosum. An update on clinical features, diagnosis and therapy","volume":"61","author":"Tr\u00e9mezaygues","year":"2010","journal-title":"Hautarzt"},{"key":"10.1111\/bjd.16485-BIB0008|bjd16485-cit-0008","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1745-6215-13-51","article-title":"UK Dermatology Clinical Trials Network's STOP GAP trial (a multicentre trial of prednisolone versus ciclosporin for pyoderma gangrenosum): protocol for a randomised controlled trial","volume":"13","author":"Craig","year":"2012","journal-title":"Trials"},{"key":"10.1111\/bjd.16485-BIB0009|bjd16485-cit-0009","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1038\/jid.2012.130","article-title":"Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study","volume":"132","author":"Langan","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1111\/bjd.16485-BIB0010|bjd16485-cit-0010","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jaad.2009.05.030","article-title":"Pyoderma gangrenosum: a review and update on new therapies","volume":"62","author":"Miller","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.16485-BIB0011|bjd16485-cit-0011","doi-asserted-by":"crossref","first-page":"h2958","DOI":"10.1136\/bmj.h2958","article-title":"Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial","volume":"350","author":"Ormerod","year":"2015","journal-title":"BMJ"},{"key":"10.1111\/bjd.16485-BIB0012|bjd16485-cit-0012","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/j.1365-2133.1997.tb01568.x","article-title":"Pyoderma gangrenosum: a report of 44 cases with follow-up","volume":"137","author":"Driesch","year":"1997","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.16485-BIB0013|bjd16485-cit-0013","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1750-1172-2-19","article-title":"Pyoderma gangrenosum - a review","volume":"2","author":"Wollina","year":"2007","journal-title":"Orphanet J Rare Dis"},{"key":"10.1111\/bjd.16485-BIB0014|bjd16485-cit-0014","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1002\/art.20559","article-title":"Therapeutic management of pyoderma gangrenosum","volume":"50","author":"Ehling","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1111\/bjd.16485-BIB0015|bjd16485-cit-0015","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jaad.2004.10.006","article-title":"Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients","volume":"53","author":"Reichrath","year":"2005","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl. 1","key":"10.1111\/bjd.16485-BIB0016|bjd16485-cit-0016","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.2310\/7750.2009.00002","article-title":"Pyoderma gangrenosum: common pitfalls in management and a stepwise, evidence-based, therapeutic approach","volume":"13","author":"Prajapati","year":"2009","journal-title":"J Cutan Med Surg"},{"key":"10.1111\/bjd.16485-BIB0017|bjd16485-cit-0017","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1111\/bjd.16485-BIB0018|bjd16485-cit-0018","unstructured":"Fleming P Partridge ACR Bai J-W Treatment of pyoderma gangrenosum: a systematic review of observational studies and clinical trials http:\/\/www.crd.york.ac.uk\/PROSPERO\/display_record.php?ID=CRD42016051234"},{"key":"10.1111\/bjd.16485-BIB0019|bjd16485-cit-0019","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/01421590903414245","article-title":"Conducting a best evidence systematic review. Part 1: From idea to data coding. BEME Guide No. 13","volume":"32","author":"Hammick","year":"2010","journal-title":"Med Teach"},{"key":"10.1111\/bjd.16485-BIB0020|bjd16485-cit-0020","unstructured":"Wells GA Shea B O'Connell D et\u00a0al The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"10.1111\/bjd.16485-BIB0021|bjd16485-cit-0021","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1111\/bjd.16485-BIB0022|bjd16485-cit-0022","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/gut.2005.074815","article-title":"Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial","volume":"55","author":"Brooklyn","year":"2006","journal-title":"Gut"},{"key":"10.1111\/bjd.16485-BIB0023|bjd16485-cit-0023","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1007\/s10620-013-2762-2","article-title":"Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease","volume":"58","author":"Arguelles-Arias","year":"2013","journal-title":"Dig Dis Sci"},{"key":"10.1111\/bjd.16485-BIB0024|bjd16485-cit-0024","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1111\/j.1572-0241.2003.07581.x","article-title":"Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease","volume":"98","author":"Regueiro","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/bjd.16485-BIB0025|bjd16485-cit-0025","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1365-2230.2010.03941.x","article-title":"Pyoderma gangrenosum: an Indian perspective","volume":"36","author":"Bhat","year":"2011","journal-title":"Clin Exp Dermatol"},{"key":"10.1111\/bjd.16485-BIB0026|bjd16485-cit-0026","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/j.1365-4632.2011.05451.x","article-title":"Pyoderma gangrenosum - a review of 24 cases observed over 10\u00a0years","volume":"52","author":"Pereira","year":"2013","journal-title":"Int J Dermatol"},{"key":"10.1111\/bjd.16485-BIB0027|bjd16485-cit-0027","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1080\/09546630410031909","article-title":"Review of 26 cases of classical pyoderma gangrenosum: clinical and therapeutic features","volume":"15","author":"Vidal","year":"2004","journal-title":"J Dermatol Treat"},{"key":"10.1111\/bjd.16485-BIB0028|bjd16485-cit-0028","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/bjd.14037","article-title":"Canakinumab in adults with steroid-refractory pyoderma gangrenosum","volume":"173","author":"Kolios","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.16485-BIB0029|bjd16485-cit-0029","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1080\/003655202320378338","article-title":"Pyoderma gangrenosum associated with Crohn disease: effect of TNF-alpha blockade with infliximab","volume":"37","author":"Ljung","year":"2002","journal-title":"Scand J Gastroenterol"},{"key":"10.1111\/bjd.16485-BIB0030|bjd16485-cit-0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00054725-200102000-00001","article-title":"Intravenous cyclosporine in refractory pyoderma gangrenosum complicating inflammatory bowel disease","volume":"7","author":"Friedman","year":"2001","journal-title":"Inflamm Bowel Dis"},{"key":"10.1111\/bjd.16485-BIB0031|bjd16485-cit-0031","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/DCR.0b013e31819accc6","article-title":"Early diagnosis and early corticosteroid administration improves healing of peristomal pyoderma gangrenosum in inflammatory bowel disease","volume":"52","author":"Funayama","year":"2009","journal-title":"Dis Colon Rectum"},{"key":"10.1111\/bjd.16485-BIB0032|bjd16485-cit-0032","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1001\/jama.284.12.1546","article-title":"Clinical features and treatment of peristomal pyoderma gansrenosum","volume":"284","author":"Hughes","year":"2000","journal-title":"JAMA"},{"key":"10.1111\/bjd.16485-BIB0033|bjd16485-cit-0033","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1067\/mjd.2000.104515","article-title":"Parastomal pyoderma gangrenosum:clinical features and management","volume":"42","author":"Lyon","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.16485-BIB0034|bjd16485-cit-0034","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jamcollsurg.2007.07.023","article-title":"Management of peristomal pyoderma gangrenosum","volume":"206","author":"Poritz","year":"2008","journal-title":"J Am Coll Surg"},{"key":"10.1111\/bjd.16485-BIB0035|bjd16485-cit-0035","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1016\/j.crohns.2012.08.001","article-title":"Risk factors for peristomal pyoderma gangrenosum complicating inflammatory bowel disease","volume":"7","author":"Wu","year":"2013","journal-title":"J Crohns Colitis"},{"key":"10.1111\/bjd.16485-BIB0036|bjd16485-cit-0036","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1365-2133.1982.tb11684.x","article-title":"Pharmacological modulation of neutrophil phagocytic function in a patient with recurrent sepsis, pyoderma gangrenosum and impaired phagocytosis","volume":"106","author":"Bentley-Phillips","year":"1982","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.16485-BIB0037|bjd16485-cit-0037","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1001\/archderm.1976.01630370072023","article-title":"Pyoderma gangrenosum, defective neutrophil chemotaxis, and leukemia","volume":"112","author":"Shore","year":"1976","journal-title":"Arch Dermatol"},{"key":"10.1111\/bjd.16485-BIB0038|bjd16485-cit-0038","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.jaad.2015.06.021","article-title":"Pathophysiology of pyoderma gangrenosum (PG): an updated review","volume":"73","author":"Braswell","year":"2015","journal-title":"J Am Acad Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.16485","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjd.16485\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T08:40:04Z","timestamp":1676364004000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/179\/2\/290\/6730923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,6]]},"references-count":38,"URL":"https:\/\/doi.org\/10.1111\/bjd.16485","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732757163.793568316","asserted-by":"object"}]},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6,6]]}}}